DP043 | AN MRD-GUIDED FRONTLINE TREATMENT FOR YOUNG PATIENTS WITH HIGH-RISK CLL INCLUDING VENETOCLAX AND OBINUTUZUMAB FOLLOWED BY VENETOCLAX AND ZANUBRUTINIB IN PATIENTS WITH DETECTABLE MINIMAL RESIDUAL DISEASE: PRELIMINARY RESULTS FROM GIMEMA CLL2222 – VIS TRIAL

A significant proportion of patients with chronic lymphocytic leukemia (CLL) who undergo a fixed-duration treatment with the venetoclax and obinutuzumab (VenO) combination achieved undetectable minimal residual disease (uMRD) with more prolonged progression-free survival than those with detectable...

Full description

Bibliographic Details

Published in:	Haematologica
Main Authors:	F.R. Mauro, I. Della Starza, A. Visentin, A. Sanna, S. Pepe, F. Russo, M. Celli, L. Laurenti, P. Sportoletti, R. Moia, C. Riemma, M. Varettoni, C. Patti, C. Stelitano, A. Arcari, M. Gentile, R. Marasca, P. Bulian, M. Tani, N. Di Renzo, P. Galieni, M.I. Del Principe, C. Vitale, G.M. Rigolin, V. Arena, M. Messina, A. Piciocchi, L. Trentin
Format:	Article
Language:	English
Published:	Ferrata Storti Foundation 2025-09-01
Online Access:	https://haematologica.org/article/view/12644